Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma with Hemophagocytic Lymphohistiocytosis (HLH)

Clinical Scenario

This protocol covers subcutaneous panniculitis-like T-cell lymphoma (SPTCL) presenting with hemophagocytic lymphohistiocytosis (HLH), systemic disease, or high tumor burden — defined as widespread subcutaneous involvement.

HLH complication: When HLH is present alongside SPTCL, concurrent treatment of HLH together with the lymphoma is recommended, with the sequencing of interventions guided by HLH severity.

First-Line Approach (partial overview)

First-line therapy may involve single-agent approaches with or without corticosteroids, or etoposide-based combination chemotherapy — with the choice and ordering shaped by the presence of HLH; radiation therapy may also be considered in selected cases.

The complete regimen — including specific agents, sequencing criteria, and transplant-eligibility considerations — is available in the full structured protocol.

Treatment Goals

The primary aim of first-line therapy is to achieve a complete response (CR) or partial response (PR).

Instant Access to Structured Evidence-Based Regimens

References

SPTCL with HLH, Systemic Disease, or High Tumor Burden (Widespread Subcutaneous Disease)

In cases complicated by HLH, treatment of HLH concurrently with treatment of lymphoma is recommended.

Single agents (CsA, pralatrexate, or romidepsin) with or without prednisone or etoposide-based combination chemotherapy regimens can be considered as options for first-line therapy.

It is recommended to start with etoposide-based regimens to control HLH first and then move to disease-specific therapies.

Involved-site radiation therapy (ISRT) can be considered for single lesion or limited disease with or without symptoms or HLH.

View source ↗